Cargando…

Lung tumour markers in oncology practice: a study of TPA and CA125

Several substances mark the course of lung cancer and may reliably help the clinician in decision-making. This is the first clinical study specifically designed to compare tissue polypeptide antigen and CA 125 tumour associated antigen. Three hundred and eighty-four new lung cancer patients (309 mal...

Descripción completa

Detalles Bibliográficos
Autores principales: Buccheri, G, Ferrigno, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376192/
https://www.ncbi.nlm.nih.gov/pubmed/12402150
http://dx.doi.org/10.1038/sj.bjc.6600577
_version_ 1782154711719215104
author Buccheri, G
Ferrigno, D
author_facet Buccheri, G
Ferrigno, D
author_sort Buccheri, G
collection PubMed
description Several substances mark the course of lung cancer and may reliably help the clinician in decision-making. This is the first clinical study specifically designed to compare tissue polypeptide antigen and CA 125 tumour associated antigen. Three hundred and eighty-four new lung cancer patients (309 males) were studied at their first clinical presentation and then strictly followed-up. Anthropometric, clinical and laboratory data – including tissue polypeptide antigen and CA 125 tumour associated antigen serum levels – were prospectively recorded. A total of 1000 tissue polypeptide antigen and CA 125 tumour associated antigen serum assays (384 pre-treatment and 616 posttreatment assays) were performed. Both tissue polypeptide antigen and CA 125 tumour associated antigen correlated significantly with the T, N and M stage descriptors at diagnosis (Rho: 0.200, 0.203, 0.263 and 0.181, 0.240, 0.276, respectively), and then with the objective response to treatment (Rho: 0.388 and 0.207, respectively). A pleural neoplastic involvement was mainly associated to an increase of CA 125 tumour associated antigen (Rho: 0.397). Both tissue polypeptide antigen and CA 125 tumour associated antigen were strongly predictive of the patients' outcome, as assessed by the univariate analysis of survival (log-rank test: 37.24 and 29.01) and several Cox' proportional hazards regression models. The two marker tests are similarly helpful and appear complementary, given the low inter-marker correlation and their independent prognostic capability. British Journal of Cancer (2002) 87, 1112–1118. doi:10.1038/sj.bjc.6600577 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2376192
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23761922009-09-10 Lung tumour markers in oncology practice: a study of TPA and CA125 Buccheri, G Ferrigno, D Br J Cancer Molecular and Cellular Pathology Several substances mark the course of lung cancer and may reliably help the clinician in decision-making. This is the first clinical study specifically designed to compare tissue polypeptide antigen and CA 125 tumour associated antigen. Three hundred and eighty-four new lung cancer patients (309 males) were studied at their first clinical presentation and then strictly followed-up. Anthropometric, clinical and laboratory data – including tissue polypeptide antigen and CA 125 tumour associated antigen serum levels – were prospectively recorded. A total of 1000 tissue polypeptide antigen and CA 125 tumour associated antigen serum assays (384 pre-treatment and 616 posttreatment assays) were performed. Both tissue polypeptide antigen and CA 125 tumour associated antigen correlated significantly with the T, N and M stage descriptors at diagnosis (Rho: 0.200, 0.203, 0.263 and 0.181, 0.240, 0.276, respectively), and then with the objective response to treatment (Rho: 0.388 and 0.207, respectively). A pleural neoplastic involvement was mainly associated to an increase of CA 125 tumour associated antigen (Rho: 0.397). Both tissue polypeptide antigen and CA 125 tumour associated antigen were strongly predictive of the patients' outcome, as assessed by the univariate analysis of survival (log-rank test: 37.24 and 29.01) and several Cox' proportional hazards regression models. The two marker tests are similarly helpful and appear complementary, given the low inter-marker correlation and their independent prognostic capability. British Journal of Cancer (2002) 87, 1112–1118. doi:10.1038/sj.bjc.6600577 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-11-04 2002-11-04 /pmc/articles/PMC2376192/ /pubmed/12402150 http://dx.doi.org/10.1038/sj.bjc.6600577 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Buccheri, G
Ferrigno, D
Lung tumour markers in oncology practice: a study of TPA and CA125
title Lung tumour markers in oncology practice: a study of TPA and CA125
title_full Lung tumour markers in oncology practice: a study of TPA and CA125
title_fullStr Lung tumour markers in oncology practice: a study of TPA and CA125
title_full_unstemmed Lung tumour markers in oncology practice: a study of TPA and CA125
title_short Lung tumour markers in oncology practice: a study of TPA and CA125
title_sort lung tumour markers in oncology practice: a study of tpa and ca125
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376192/
https://www.ncbi.nlm.nih.gov/pubmed/12402150
http://dx.doi.org/10.1038/sj.bjc.6600577
work_keys_str_mv AT buccherig lungtumourmarkersinoncologypracticeastudyoftpaandca125
AT ferrignod lungtumourmarkersinoncologypracticeastudyoftpaandca125